HC Wainwright Reiterates “Neutral” Rating for HilleVax (NASDAQ:HLVX)

HilleVax (NASDAQ:HLVX)‘s stock had its “neutral” rating reaffirmed by equities researchers at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $2.00 price objective on the stock. HC Wainwright’s price target points to a potential upside of 16.96% from the stock’s previous close.

Other research analysts also recently issued research reports about the company. Stifel Nicolaus downgraded HilleVax from a “buy” rating to a “hold” rating and reduced their target price for the stock from $34.00 to $3.00 in a report on Tuesday, July 9th. Guggenheim downgraded shares of HilleVax from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Leerink Partnrs lowered shares of HilleVax from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 9th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $5.00 price target (down from $24.00) on shares of HilleVax in a research report on Monday, July 8th. Finally, SVB Leerink downgraded shares of HilleVax from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $28.00 to $2.00 in a research report on Tuesday, July 9th. Six equities research analysts have rated the stock with a hold rating, According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $9.20.

HilleVax Stock Up 7.5 %

HLVX stock opened at $1.71 on Monday. The company has a market capitalization of $85.02 million, a P/E ratio of -0.52 and a beta of 0.80. The firm has a 50 day simple moving average of $7.34 and a 200-day simple moving average of $12.30. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. HilleVax has a twelve month low of $1.55 and a twelve month high of $20.22.

HilleVax (NASDAQ:HLVX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.10). On average, equities research analysts predict that HilleVax will post -2.58 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $14.73, for a total value of $88,380.00. Following the completion of the transaction, the director now directly owns 764,878 shares of the company’s stock, valued at approximately $11,266,652.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 71.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. EntryPoint Capital LLC acquired a new stake in HilleVax in the first quarter worth about $80,000. SG Americas Securities LLC acquired a new stake in shares of HilleVax in the 4th quarter worth approximately $139,000. Tidal Investments LLC bought a new position in shares of HilleVax in the first quarter valued at approximately $207,000. abrdn plc acquired a new position in shares of HilleVax during the fourth quarter valued at approximately $433,000. Finally, Swiss National Bank raised its holdings in HilleVax by 22.4% during the fourth quarter. Swiss National Bank now owns 38,200 shares of the company’s stock worth $613,000 after purchasing an additional 7,000 shares in the last quarter. Institutional investors own 86.42% of the company’s stock.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.